ESBATech's Acquisition

ESBATech was acquired by Alcon on September 13, 2009.

ESBATech develops therapeutic single-chain fragment antibodies on the basis of its fully human antibody fragments for the treatment of various inflammatory diseases. The established know-how and exper…

Articles about ESBATech's Acquisition: